Want to see NGEN full AI Analyst Report?
Top Page
NervGen Pharma
(NASDAQ:NGEN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▲(13.12% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance: no revenue, widening losses, and rising cash burn that imply continued reliance on external funding despite low debt. Technicals provide some offset with a strong short-term uptrend, but overbought signals and weaker longer-term trend reduce that support. Valuation is also constrained by negative earnings and the absence of a dividend.
Positive Factors
Low Financial Leverage
Minimal debt reduces fixed financial obligations and interest-related pressure, giving NervGen greater flexibility to direct capital toward clinical development while limiting balance-sheet risk during its pre-revenue phase.
Negative Factors
Pre-Revenue Business Model
NervGen has no recurring product revenue to fund research, clinical trials, or corporate costs. Its long-term prospects therefore depend on successful development, regulatory progress, and eventual partnering or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Minimal debt reduces fixed financial obligations and interest-related pressure, giving NervGen greater flexibility to direct capital toward clinical development while limiting balance-sheet risk during its pre-revenue phase.
Read all positive factors
NervGen Pharma (NGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$251.07M
Dividend YieldN/A
Average Volume (3M)818.53K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS Growth-96.62%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding107,522,640
10 Day Avg. Volume880,572
30 Day Avg. Volume818,526
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside465.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
NervGen Pharma Business Overview & Revenue Model
Company Description
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product...
How the Company Makes Money
NervGen Pharma does not have a mature commercial product portfolio; as a clinical-stage biotech, it is primarily focused on advancing its drug candidates through clinical development rather than generating recurring product sales. Information indi...
NervGen Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.52K | 0.00 | -83.74K | -145.01K | -114.10K | -42.95K |
| EBITDA | -11.61M | -5.65M | -23.91M | -22.24M | -19.92M | -12.78M |
| Net Income | -67.56M | -44.12M | -23.99M | -22.38M | -20.54M | -12.82M |
Balance Sheet | ||||||
| Total Assets | 90.34M | 23.21M | 19.47M | 13.24M | 23.67M | 18.03M |
| Cash, Cash Equivalents and Short-Term Investments | 86.93M | 22.07M | 17.35M | 11.66M | 22.25M | 17.06M |
| Total Debt | 0.00 | 8.37K | 105.53K | 197.21K | 280.96K | 0.00 |
| Total Liabilities | 73.03M | 19.73M | 16.90M | 15.25M | 10.32M | 1.09M |
| Stockholders Equity | 17.31M | 3.48M | 2.57M | -2.01M | 13.34M | 16.95M |
Cash Flow | ||||||
| Free Cash Flow | -29.60M | -19.50M | -16.83M | -11.30M | -17.65M | -8.33M |
| Operating Cash Flow | -29.60M | -19.50M | -16.83M | -11.30M | -17.63M | -8.33M |
| Investing Cash Flow | 80.48K | 100.93K | 58.83K | -138.87K | -20.92K | -45.43K |
| Financing Cash Flow | 102.69M | 23.76M | 22.68M | 766.35K | 22.44M | 19.76M |
NervGen Pharma Peers Comparison
UnderperformOutperform
Sector (51)
NGEN
NervGen Pharma
2.28
-0.38
-14.29%
TSE:DRUG
Bright Minds Biosciences
101.61
43.00
73.37%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.25
-3.75
-93.75%
TSE:NURL
Neural Therapeutics Inc.
0.02
>-0.01
-25.00%
NervGen Pharma Corporate Events
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
Aug 13, 2026
NervGen Pharma Corp., a Vancouver-based biotechnology company specializing in nervous system repair therapeutics, reported its unaudited condensed consolidated interim financial results for the three- and six-month periods ended June 30, 2026, alo...
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
Jul 2, 2026
On July 2, 2026, NervGen Pharma filed a Form 6-K with the U.S. Securities and Exchange Commission to report a new sales agreement with Leerink Partners LLC. Under this agreement, NervGen may issue and sell up to US$50 million of its common shares ...
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
Jun 1, 2026
On May 21, 2026, NervGen Pharma priced an underwritten U.S. public offering of 24 million common shares and accompanying warrants, raising approximately US$60 million in gross proceeds. The securities were offered at US$2.50 per share and warrant,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.